Abstract:
Compounds represented by the following formula I: ##STR1## in which: R.sup.1 to R.sup.5 can have various meanings of which alkyl, substituted or non-substituted aryl, and m is equal to 0 or 1, X is selected from (CR.sup.6 R.sup.7).sub.n in which n=0 or 1, and CO are disclosed. These compounds are useful as anti-tumor drugs, especially with pro-oxidizing activity.
Abstract translation:由下式I表示的化合物:其中:R 1至R 5可以具有其中烷基,取代或未取代的芳基,m等于0或1的各种含义,X选自(CR 6 R 7)n,其中n = 0或1,并公开CO。 这些化合物可用作抗肿瘤药物,特别是具有促氧化活性。
Abstract:
The invention concerns novel benzisoselen-azoline and -azine derivatives. These novel derivatives have the following general formula (II): ##STR1## where: R.sup.1 to R.sup.8 and R.sup.10 have various meanings, in particular H, alkyl, etc . . . ; ##STR2## Y.sup.- represents the anion of a pharmaceutically acceptable anion; n=0, 1; m=0, 1, 2; p=1, 2, 3; q=2, 3, 4; r=0, 1; and their pharmaceutically acceptable salts of acids or bases; there being no more than one substituent R.sup.9 in each molecule with general formula II. These novel derivatives can be used in medication.
Abstract translation:PCT No.PCT / FR95 / 00447 Sec。 371日期1996年1月30日 102(e)日期1996年1月30日PCT提交1995年4月7日PCT公布。 WO95 / 27706 PCT公开号 日期1995年10月19日本发明涉及新型苯并异硒咯啉和吖嗪衍生物。 这些新型衍生物具有以下通式(II):其中:R1至R8和R10具有各种含义,特别是H,烷基等。 。 。 ; Y-表示药学上可接受的阴离子的阴离子; n = 0,1; m = 0,1,2; p = 1,2,3。 q = 2,3,4; r = 0,1; 及其药学上可接受的酸或碱的盐; 在每个具有通式II的分子中,不超过一个取代基R9。 这些新型衍生物可用于药物治疗。
Abstract:
The present invention provides a novel pharmaceutical use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent suppressive effect on retinal ganglion cell death in a pharmacological test using rats, and is therefore useful as a prophylactic or therapeutic agent for an eye disease accompanied by optic nerve disorder.
Abstract:
The invention relates to compounds and compositions to treat some neurodegenerative diseases. In some embodiments, the invention relates to an antioxidant comprising a selenium atom and nitroxide group. In further embodiments, the antioxidant comprises peroxidase and superoxide dismutase activity. In some embodiments, the antioxidants are effective in treating neurodegenerative diseases including, but not limited to, Alzheimer's disease, Parkinson's disease, or multiple sclerosis. In additional embodiments, the invention relates to using compounds disclosed herein as free radical electromagnetic imaging agents.
Abstract:
The invention is directed to novel cyclic organoselenium compounds useful as antioxidants, pharmaceutical compositions containing them, and methods for their preparation.
Abstract:
Compounds represented by the following formula I: in which: R1 to R5 can have various meanings of which alkyl, substituted or non-substituted aryl, and m is equal to 0 or 1, X is selected from (CR6R7)n in which n=0 or 1, and CO are disclosed. These compounds are useful as anti-tumor drugs, especially with pro-oxidizing activity.
Abstract translation:由下式I表示的化合物:其中:R 1至R 5可以具有其中烷基,取代或未取代的芳基,m等于0或1的各种含义,X选自(CR 6 R 7)n,其中n = 0或1,并公开CO。 这些化合物可用作抗肿瘤药物,特别是具有促氧化活性。
Abstract:
Methylpiperazinoazepine derivatives corresponding to formula (I): ##STR1## wherein the symbols X, R.sub.1, R.sub.2, N.sub.1 and N.sub.2 have different meanings and pharmaceutically acceptable salts thereof, preparation and use thereof.
Abstract:
Phenothiazone derivatives and analogs thereof, pharmaceutical compositions and methods of treatment are disclosed. These compounds are useful as inhibitors of mammalian leukotriene biosynthesis. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders and inflammation.
Abstract:
Compounds represented by the following formula I: ##STR1## in which: R.sup.1 to R.sup.5 can have various meanings of which alkyl, substituted or non-substituted aryl, and m is equal to 0 or 1, X is selected from (CR.sup.6 R.sup.7).sub.n in which n=0 or 1, and CO are disclosed. These compounds are useful as anti-tumor drugs, especially with pro-oxidizing activity.
Abstract translation:由下式I表示的化合物:其中:R 1至R 5可以具有其中烷基,取代或未取代的芳基,m等于0或1的各种含义,X选自(CR 6 R 7)n,其中n = 0或1,并公开CO。 这些化合物可用作抗肿瘤药物,特别是具有促氧化活性。
Abstract:
A process for preparing an alkyl sulfonate derivative comprises causing a nitrogen-containing heterocyclic compound represented by the following formula (1): ##STR1## wherein X represents --O--, --S--, --NR.sup.1 --, --Se--, --Te-- or --CR.sup.2 R.sup.3 --, in which each of R.sup.1, R.sup.2 and R.sup.3 independently represents a hydrogen atom or a lower alkyl group, Y represents a hydrogen atom, a mercapto group, an arylthio group, an aralkyl group, a sulfo group, a halogen atom, an alkyl group, an alkylthio group, an alkylsulfonyloxy group or an arylsulfonyloxy group and each of R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 represents a hydrogen atom, an alkyl group, an aryl group, an alkoxy group which may be substituted with a sulfo group, an aryloxy group, an alkylthio group, a haloalkyl group, a halogen atom, a cyano group, a carboxy group or a sulfo group, otherwise R.sup.4 and R.sup.5, R.sup.6 and R.sup.6, R.sup.6 and R.sup.7 and R.sup.7 and R.sup.8 are, in at least one of these combinations, bonded each other to form an aromatic ring or a cycloalkene ring; to react in the presence of Lewis acid with an aliphatic sultone to give an alkyl sulfonate derivative corresponding to the above formula (1).